immuron limited, page-3

I’m sorry, but a post suggesting PXS will be $1 ‘just because’ in the next quarter is misleading and dangerous. I am a strong believer in PXS and am incredibly excited about the upcoming results across a range of clinical studies, but a share price of $1 translates into a market cap of over $300m. Pharmaxis at $300m from my perspective requires the business to either (i) have a much clearer path to profitability; or (ii) some form of corporate action. In my view, for either of the above to occur, we will require positive results from the upcoming phase 1 and/or phase 2 trials. Bronchitol and Aridole, whilst starting to get closer to break-even point are, again in my view, unlikely to deliver substantial returns, however if they can assist in slowing the cash burn over the remainder of the year, that will be a major positive.